"At this time, the Fund will help to address the victims' families'
immediate and urgent needs. In the long-run however, we hope the Fund
will be able to help employees in need of support." Neptune
Technologies & Bioressources
LAVAL, QC, Dec. 11, 2012 /CNW Telbec/ - Following the incident that
occurred on November 8th, Neptune Technologies & Bioressources has created the Fonds d'Entraide Neptune Technologies, a victims fund to help its employees. The Fund, in the form of a
non-profit legal person (NPO) will allow raising money from companies
and individuals who wish to show their support. "The victims fund
created is already active. Neptune has invested more than $200,000 and
has thus, among other, allowed the payment of employees' salary for the
period of November 8th to November 21st. Furthermore, we were able to take over and help with quite a few
urgent requests by the victims' families which included transportation
to the hospitals, help with the funerals and others," added Mr. Michel
Chratrand, Chief operating officer and president of the committee in
charge of the constitution and organization of the Fonds d'Entraide Neptune Technologies.
Since the event of November 8th, many companies and individuals have voiced their will to help the
employees. The creation of a NPO allows Neptune to raise these funds
directly and to redistribute them judiciously. The structure put in
place allows Neptune to better inform the business community and
individuals sensitized by this tragic incident that they can send their
donations made out to the Fonds d'Entraide Neptune Technologies, by mail to the following address: 545, Promenade du Centropolis, Laval, (Quebec)
H7T 0A3. The fund will allow the company to address pressing needs, but
also certain long-term demands from the employees in need.
About Neptune Technologies & Bioressources
Neptune is a biotechnology company engaged primarily in the development
and commercialization of marine derived omega-3 polyunsaturated fatty
acids, or PUFAs. Neptune has a patented process of extracting oils from
Antarctic krill, which omega-3 PUFAs are then principally sold as bulk
oil to Neptune's distributors who commercialize them under their
private label primarily in the U.S., European and Asian neutraceutical
markets. Neptune's lead products, Neptune Krill Oil (NKO®) and ECOKRILL
Oil (EKO™), generally come in capsule form and serve as a dietary
supplement to consumers.
Through its subsidiaries Acasti (TSXV: APO) and NeuroBio, in which
Neptune respectively holds 57% and 99% of the voting rights, Neptune is
also pursuing opportunities in the medical food and prescription
drugmarkets. Acasti and NeuroBio respectively focus on the research and
development of safe and therapeutically effective compounds for highly
prevalent atherosclerotic conditions, such as cardiometabolic disorders
and cardiovascular diseases, and for neurodegenerative and inflammation
related conditions. Acasti's lead prescription drug candidate is
CaPre®, a purified high omega-3 phospholipid concentrate derived from
Neptune krill oil being developed to address the prevention and
treatment of cardiometabolic disorders, including hypertriglyceridemia,
which is characterized by abnormally high levels of triglycerides.
SOURCE: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
For further information: